Expressions, immune associations, and prognostic values of mitochondrial ribosomal protein MRPL3 in the pan cancer landscape.

IF 2.9 4区医学 Q3 ENDOCRINOLOGY & METABOLISM

Discover. Oncology Pub Date : 2025-10-21 DOI:10.1007/s12672-025-03770-y

Jing Lin, Wenzhe Chen, Yaodong Zhao, GuanZhong Qiu

{"title":"Expressions, immune associations, and prognostic values of mitochondrial ribosomal protein MRPL3 in the pan cancer landscape.","authors":"Jing Lin, Wenzhe Chen, Yaodong Zhao, GuanZhong Qiu","doi":"10.1007/s12672-025-03770-y","DOIUrl":null,"url":null,"abstract":"Background: MRPL3, a member of the mitochondrial ribosomal family, is involved in the translation of mitochondria-related proteins. However, its role in tumors remains unclear.Objective: To elucidate the oncogenic role and prognostic significance of MRPL3 in cancer.Methods: We conducted a pan-cancer analysis of MRPL3 using various databases, bioinformatics and statistical tools, as well as tissue microarray analysis.Results: MRPL3 was generally upregulated in tumors compared to normal tissues. Its expression showed a negative correlation with immunogenic markers, immune cell infiltration, and immune checkpoint genes (ICGs) in most cancers, suggesting an immunosuppressive role in the tumor microenvironment (TME). Genes interacting with and similar to MRPL3 were involved in key signaling pathways across cancers. MRPL3 overexpression was frequently associated with poor prognosis and identified as an independent prognostic risk factor in KIRC, LUSC, LIHC, MESO, UCEC, and PAAD.Conclusion: MRPL3 is overexpressed in multiple cancers and plays an immunosuppressive role, significantly correlating with poor prognosis, indicating its potential as a therapeutic target in cancer treatment.","PeriodicalId":11148,"journal":{"name":"Discover. Oncology","volume":"16 1","pages":"1928"},"PeriodicalIF":2.9000,"publicationDate":"2025-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12540236/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Discover. Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s12672-025-03770-y","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

Background: MRPL3, a member of the mitochondrial ribosomal family, is involved in the translation of mitochondria-related proteins. However, its role in tumors remains unclear.

Objective: To elucidate the oncogenic role and prognostic significance of MRPL3 in cancer.

Methods: We conducted a pan-cancer analysis of MRPL3 using various databases, bioinformatics and statistical tools, as well as tissue microarray analysis.

Results: MRPL3 was generally upregulated in tumors compared to normal tissues. Its expression showed a negative correlation with immunogenic markers, immune cell infiltration, and immune checkpoint genes (ICGs) in most cancers, suggesting an immunosuppressive role in the tumor microenvironment (TME). Genes interacting with and similar to MRPL3 were involved in key signaling pathways across cancers. MRPL3 overexpression was frequently associated with poor prognosis and identified as an independent prognostic risk factor in KIRC, LUSC, LIHC, MESO, UCEC, and PAAD.

Conclusion: MRPL3 is overexpressed in multiple cancers and plays an immunosuppressive role, significantly correlating with poor prognosis, indicating its potential as a therapeutic target in cancer treatment.

查看原文本刊更多论文

线粒体核糖体蛋白MRPL3在泛癌症领域的表达、免疫关联和预后价值

背景：MRPL3是线粒体核糖体家族的一员，参与线粒体相关蛋白的翻译。然而，它在肿瘤中的作用仍不清楚。目的：探讨MRPL3在肿瘤中的致癌作用及预后意义。方法：利用各种数据库、生物信息学和统计工具以及组织微阵列分析对MRPL3进行泛癌分析。结果：与正常组织相比，MRPL3在肿瘤中普遍上调。在大多数癌症中，其表达与免疫原性标志物、免疫细胞浸润和免疫检查点基因（ICGs）呈负相关，提示其在肿瘤微环境（TME）中具有免疫抑制作用。与MRPL3相互作用和相似的基因参与了癌症的关键信号通路。MRPL3过表达通常与不良预后相关，并被确定为KIRC、LUSC、LIHC、MESO、UCEC和PAAD的独立预后危险因素。结论：MRPL3在多种肿瘤中过表达，具有免疫抑制作用，与不良预后显著相关，可能成为肿瘤治疗的治疗靶点。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊